Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Friday, September 12, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences presented data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium. The company highlighted the potential of its ARCUS platform in addressing significant unmet medical needs. The presentation marks a key milestone in their clinical development efforts.
Price reaction · baseline $5 (2025-09-11 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
-7.8%
day 1 · peak
-10%
day 3
-9.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of promising data from Phase 1 trial
  • Focus on high unmet need diseases
  • Utilization of novel ARCUS platform

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Sep. 12, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company presented

Frequently Asked Questions

What is the ELIMINATE-B trial?

The ELIMINATE-B trial is a Phase 1 clinical study for PBGENE-HBV by Precision BioSciences.

What platform does Precision BioSciences use?

Precision BioSciences utilizes its proprietary ARCUS platform for gene editing therapies.

Where was the trial data presented?

The trial data was presented at the 6th International Coalition to Eliminate HBV Cure Symposium.

What is the focus of PBGENE-HBV?

PBGENE-HBV focuses on addressing high unmet medical needs related to HBV.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences PBGENE-HBV ARCUS platform Phase 1 trial
Last updated: Sep 12, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →